PubMed Health⌕ Search

Biomedical subjects

J Cardea

Publications and source records attributed to J Cardea.

4 recordsLinked to original sources

Ketorolac versus meperidine for pain relief after orthopaedic surgery.

In this double-blind, randomized, multicenter study, 244 patients with at least moderate pain after major orthopaedic surgery received intramuscular Ketorolac (60 mg followed by 30 mg) or intramuscular meperidine (100 mg or placebo) every 2 to 6 hours as needed for as many as 5 days. Analgesic response was evaluated for 6 hours after initial study drug administration and thereafter each night at bedtime. Both active treatment groups had similar 3-hour summed pain intensity difference and 3-hour total pain relief scores after the first dose that were superior to placebo. The 6-hour summed pain intensity difference and total pain relief scores were significantly higher with Ketorolac than with meperidine or placebo. The mean daily categorical pain intensity scores were comparable with Ketorolac and meperidine, and both were significantly superior to placebo. Patient ratings of overall medication efficacy were significantly better with Ketorolac than with meperidine. In both patient and observer evaluations, Ketorolac was significantly better tolerated than meperidine, and the number of patients reporting adverse events was lower with Ketorolac than with meperidine. Following major orthopaedic surgery, Ketorolac provided effective analgesia that was superior to placebo and at least comparable with meperidine. Ketorolac was better tolerated than meperidine.

Adolescent↗

Comparative penetration of latamoxef (moxalactam) and cefazolin into human knee following simultaneous administration.

The penetration of latamoxef (moxalactam) and cefazolin into cancellous bone was compared in ten adult patients undergoing total knee replacement. Each patient received a ten milligram per kilogram bolus dose of both antibiotics at the induction of anaesthesia. Antibiotic bone concentrations were determined by HPLC. The mean serum concentrations of cefazolin were significantly greater (P less than 0.01) than those of latamoxef at all time periods. The absolute bone concentrations of cefazolin and latamoxef did not differ significantly (P greater than 0.05). The method of simultaneous administration offers significant advantages over the conventional two group study design.

Adult↗

Penetration of moxalactam and cefazolin into bone following simultaneous bolus or infusion.

The penetration of cefazolin and moxalactam into bone was studied in 20 adults scheduled for total hip arthroplasty. Patients randomly received both moxalactam and cefazolin (10 mg/kg of each) by either a rapid bolus or a 30-minute infusion. Serum and bone-extract concentrations were measured by HPLC. Serum concentrations of cefazolin were significantly greater than those of moxalactam at 15 minutes, 30 minutes, and at the time of bone removal for both rates of injection. Bone concentrations of cefazolin were significantly greater than those of moxalactam for both the bolus study (7.7 +/- 4.8 micrograms/g versus 5.4 +/- 3.4 micrograms/g) and the infusion study (5.6 +/- 3.4 micrograms/g versus 4.3 +/- 2.6 micrograms/g, respectively). There was no significant difference in the bone levels for the two drugs when penetration was expressed as a function of the simultaneous serum concentration (18% for each drug), and there were no significant differences in bone concentrations between the two rates of administration.

Adult↗